Targeting Mitochondrial Dysfunction
Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.
View Candidate
Innovative Pipeline of First-In-Class Products
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View Pipeline
Backed by Strong Leadership
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
Latest News
Poxel Successfully Raises €17.7 Million in a Capital Increase
LYON, France--(BUSINESS WIRE)--POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes…
Read this Press Release: Poxel Successfully Raises €17.7 Million in a Capital IncreasePoxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases
PXL770, a novel direct AMPK activator, produced additive benefits in a NASH model when combined with other late-stage agents in development PXL770 treatment was observed to improve cardio-renal disease and…
Read this Press Release: Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic DiseasesPoxel Announces Notice of its Annual General Meeting to be Held on June 24, 2020
LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…
Read this Press Release: Poxel Announces Notice of its Annual General Meeting to be Held on June 24, 2020
Upcoming Events
Jefferies Virtual Healthcare Conference
European Association for the Study of the Liver 2020 International Liver Congress
